Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
Leukemia. 2020 Jun;34(6):1599-1612. doi: 10.1038/s41375-020-0714-3. Epub 2020 Jan 23.
Leukemia. 2020.
PMID: 31974435
Free PMC article.
Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression.
Quijada-Álamo M, Hernández-Sánchez M, Rodríguez-Vicente AE, Pérez-Carretero C, Rodríguez-Sánchez A, Martín-Izquierdo M, Alonso-Pérez V, García-Tuñón I, Bastida JM, Vidal-Manceñido MJ, Galende J, Aguilar C, Queizán JA, González-Gascón Y Marín I, Hernández-Rivas JÁ, Benito R, Ordóñez JL, Hernández-Rivas JM.
Quijada-Álamo M, et al. Among authors: alonso perez v.
Blood Cancer J. 2021 Jul 9;11(7):127. doi: 10.1038/s41408-021-00520-5.
Blood Cancer J. 2021.
PMID: 34244476
Free PMC article.
Item in Clipboard
The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia.
García-Tuñón I, Hernández-Sánchez M, Ordoñez JL, Alonso-Pérez V, Álamo-Quijada M, Benito R, Guerrero C, Hernández-Rivas JM, Sánchez-Martín M.
García-Tuñón I, et al. Among authors: alonso perez v.
Oncotarget. 2017 Apr 18;8(16):26027-26040. doi: 10.18632/oncotarget.15215.
Oncotarget. 2017.
PMID: 28212528
Free PMC article.
Item in Clipboard
Splice donor site sgRNAs enhance CRISPR/Cas9-mediated knockout efficiency.
García-Tuñón I, Alonso-Pérez V, Vuelta E, Pérez-Ramos S, Herrero M, Méndez L, Hernández-Sánchez JM, Martín-Izquierdo M, Saldaña R, Sevilla J, Sánchez-Guijo F, Hernández-Rivas JM, Sánchez-Martín M.
García-Tuñón I, et al. Among authors: alonso perez v.
PLoS One. 2019 May 9;14(5):e0216674. doi: 10.1371/journal.pone.0216674. eCollection 2019.
PLoS One. 2019.
PMID: 31071190
Free PMC article.
Item in Clipboard
ETV6/RUNX1 Fusion Gene Abrogation Decreases the Oncogenicity of Tumour Cells in a Preclinical Model of Acute Lymphoblastic Leukaemia.
Montaño A, Ordoñez JL, Alonso-Pérez V, Hernández-Sánchez J, Santos S, González T, Benito R, García-Tuñón I, Hernández-Rivas JM.
Montaño A, et al. Among authors: alonso perez v.
Cells. 2020 Jan 15;9(1):215. doi: 10.3390/cells9010215.
Cells. 2020.
PMID: 31952221
Free PMC article.
Item in Clipboard
CRISPR-Cas9 Technology as a Tool to Target Gene Drivers in Cancer: Proof of Concept and New Opportunities to Treat Chronic Myeloid Leukemia.
Vuelta E, Ordoñez JL, Alonso-Pérez V, Méndez L, Hernández-Carabias P, Saldaña R, Sevilla J, Sebastián E, Muntión S, Sánchez-Guijo F, Hernández-Rivas JM, García-Tuñón I, Sánchez-Martín M.
Vuelta E, et al. Among authors: alonso perez v.
CRISPR J. 2021 Aug;4(4):519-535. doi: 10.1089/crispr.2021.0009.
CRISPR J. 2021.
PMID: 34406033
Item in Clipboard
Suppression of metastatic organ colonization and antiangiogenic activity of the orally bioavailable lipid raft-targeted alkylphospholipid edelfosine.
Alonso-Pérez V, Hernández V, Calzado MA, Vicente-Blázquez A, Gajate C, Soler-Torronteras R, DeCicco-Skinner K, Sierra A, Mollinedo F.
Alonso-Pérez V, et al.
Biomed Pharmacother. 2024 Feb;171:116149. doi: 10.1016/j.biopha.2024.116149. Epub 2024 Jan 24.
Biomed Pharmacother. 2024.
PMID: 38266621
Free article.
Item in Clipboard
Preparation and characterization of triclosan nanoparticles for periodontal treatment.
Piñón-Segundo E, Ganem-Quintanar A, Alonso-Pérez V, Quintanar-Guerrero D.
Piñón-Segundo E, et al. Among authors: alonso perez v.
Int J Pharm. 2005 Apr 27;294(1-2):217-32. doi: 10.1016/j.ijpharm.2004.11.010.
Int J Pharm. 2005.
PMID: 15814246
Item in Clipboard
Cite
Cite